Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peanut SLIT-tablet in Adults, Adolescents, and Children With Peanut Allergy
NCT05440643Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Sep 2022
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of peanut sublingual immunotherapy tablet in peanut allergy (13 arms), sponsored by ALK-Abelló. Primary endpoints: Dose tolerability response rate and Tolerated Dose 600 mg response rate at 48 weeks. Started Sep 2022; status: completed.
02
Drugs
peanut sublingual immunotherapy tablet
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT05440643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440643.